---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023588"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:49:58.394999+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Protagenic Therapeutics restructures, cuts ~$8M annual costs; CEO and COO terminated

## Summary
- Board approved restructuring to virtual model, focusing on PT00114 Phase 2 trial expected to complete in 9–12 months.
- Annual operating expenses to be reduced by ~$8 million when fully implemented; one-time charges not yet estimable.
- CEO Barrett Evans and COO Colin Stott terminated effective immediately; both remain on the Board.
- All preclinical programs (PHYX-001 through PHYX-005) paused; company pursuing partnerships or out-licensing.
- Fiscal year-end changed from Dec 31 to Mar 31; transition report on Form 10-QT for Apr 1–Jun 30, 2025.

## SEC filing metadata
- accession: 0001641172-25-023588
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02, 5.03, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000164117225023588/0001641172-25-023588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000164117225023588/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023588
- JSON: https://secwatch.observer/filing/0001641172-25-023588.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023588.txt

## Key facts
- Governance Changes
  Protagenic Therapeutics, Inc.new: Fiscal year-end changed from December 31 to March 31.
  - Change: fiscal year change
  source text: the Board approved a change in the Company’s fiscal year-end from December 31 to March 31, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1022899/000164117225023588/0001641172-25-023588-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.